查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞健康筛查市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1190262

细胞健康筛查市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Cellular Health Screening Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，细胞健康筛查市场预计将以 8% 的复合年增长率增长。

COVID-19 在研究期间对市场增长产生了重大影响。 在大流行期间，全球人口对预防卫生意识的提高正在推动市场的增长。 根据 2022 年 6 月发表的 NCBI 论文，过去 12 个月进行的最常见测试是血压测量 83%、血糖水平 66.2%、尿检 53.1% 和体液检查 55.1%。我来了。 预计大流行期间进行的大量预防性检查将有助于市场增长。 此外，即使在大流行之后，由于人们对预防医学的兴趣日益浓厚，对细胞学的需求也不会下降，预计这将有助于未来五年的市场增长。

市场的增长归因于细胞健康筛查在个性化医疗中的应用越来越广泛，以及政府对预防医学的兴趣日益浓厚。 细胞健康筛查在个性化医疗中的潜在应用为该领域的市场参与者提供了重要的增长机会。 随着老年人口的迅速增加，预计在预测期内对细胞筛选的需求将会增加。 根据世界卫生组织 2021 年 10 月的报告，到 2030 年，地球上将有六分之一的人超过 60 岁。 60 岁及以上的人口预计将从 2020 年的 10 亿增长到 2050 年的 14 亿。 到 2050 年，世界 60 岁以上人口将翻一番，达到 21 亿。 2020 年至 2050 年间，80 岁及以上的人口数量预计将增加两倍，达到 4.26 亿。 随着人口老龄化的加剧，它变得更容易患上慢性病，从而增加了对预防性诊断的需求，尤其是细胞健康筛查。

此外，慢性病负担的增加和细胞生物标誌物意识的提高也有望促进市场增长。 根据 Globocan 2020 情况说明书，全球估计有 19,292,789 例新诊断的癌症病例。 此外，据国际癌症研究机构 (IARC) 估计，到 2040 年，全球癌症负担预计将上升至 2750 万新发癌症病例。 由于需要有效的早期诊断，癌症等慢性病的增加推动了对细胞健康筛查的需求，预计将有助于预测期内的市场增长。

因此，上述因素预计将在预测期内推动市场增长。 然而，与样品运输相关的风险预计将在预测期内抑制增长。

细胞健康筛查的市场趋势

在预测期内，端粒检测领域预计将占据重要的市场份额

预计端粒检测领域将主导市场。 这些panel将被用于获取更准确的信息，并帮助进行细胞健康筛查测试以测量端粒长度，从而预防疾病，从而在细胞健康筛查市场中占据更大的份额。 此外，随着老年人口的增加，端粒测试的偏好预计会增加，因为它有助于个人检查他们的细胞年龄，从而采取预防措施，从而促进市场的增长。

根据 2021 年 1 月发表的 Frontiers 研究，端粒是使用最广泛的衰老分子生物标誌物。 为了提高用于确定端粒长度的方法的灵敏度、可重复性和通量，单细胞端粒测量技术和基于 DNA 甲基化的端粒长度估计方法旨在识别极短的端粒。创新方法，如 基于端粒的测试的此类应用以及灵敏度提高的端粒测试的开发预计将在预测期内促进该部门的增长。

市场参与者为满足日益增长的端粒检测需求而增加的活动（例如产品发布）预计也将促进该细分市场的增长。 例如，2021 年 8 月，TruDiagnostics 为其表观遗传测试服务 TruAge 发布了一个新的报告扩展。 这种扩展允许根据甲基化准确估计端粒长度。 因此，上述因素预计将在预测期内促进该部门的增长。

北美有望在预测期内主导细胞健康筛查市场

由于患者数量众多且疾病流行率不断上升，预计北美将占据细胞健康筛查市场的很大份额。

根据 Globocon 2020，2020 年美国将有 2,281,658 名新诊断的癌症患者。 在所有癌症中，乳腺癌的发病率最高，为 253,465 例，其次是肺癌（227,875 例）、前列腺癌（209,512 例）和结肠癌（101,809 例）。 此外，根据美国癌症协会2022年公布的数据，2022年美国总共将新增190万癌症患者确诊。 慢性病的这种增加预计将推动对细胞健康筛查的需求，从而实现有效的早期诊断，从而促进市场增长。

此外，美国疾病控制与预防中心 (CDC) 于 2022 年 7 月更新的数据显示，冠心病是美国 20 岁及以上成年人最常见的心脏病类型。约有 2010 万人们已被证明患有这种疾病。 根据 CDC 2022 年 10 月的数据，每 40 秒就有一人心脏病发作，美国每年有近 805,000 人心脏病发作。 因此，心血管疾病的高负担要求提供细胞健康筛查以进行早期诊断，从而推动市场增长。

细胞健康筛查市场竞争分析

由于多家公司在全球和区域开展业务，细胞健康筛查市场呈碎片化状态。 全球参与者包括 Bio-Reference Laboratories Inc.、Genova Diagnostics、Immundiagnostik AG、Quest Diagnostics、SpectraCell Laboratories Inc. 和 Telomere Diagnostics Inc. 等公司。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 扩大细胞健康筛查在个性化医疗中的应用
    • 提高政府对预防保健的关注
  • 市场製约因素
    • 与运输样品相关的风险
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按类型
    • 单个测试面板
      • 端粒测试
      • 氧化应激测试
      • 炎症测试
      • 重金属检测
    • 多测试面板
  • 按样本类型
    • 血样
    • 尿样
    • 其他样本类型
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Bio-Reference Laboratories, Inc.（OPKO Health）
    • Genova Diagnostics
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics
    • Segterra Inc.
    • SpectraCell Laboratories Inc.
    • Telomere Diagnostics Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 67413

The cellular health screening market is expected to register a CAGR of 8% over the forecast period.

COVID-19 has had a significant impact on the growth of the market over the study period. The rise in preventive health awareness among the global population during the pandemic drives the growth of the market. According to the NCBI article published in June 2022, the most common tests performed in the past 12 months were 83% of blood pressure measurements, 66.2% of blood sugar, 53.1% of urinalysis, and 55.1% of liquid panel. The high number of preventive health screenings during the pandemic is expected to contribute to the growth of the market. In addition, the demand for cellular health screening is expected to remain undisturbed during the post-pandemic period owing to the rising preference for preventive healthcare, thereby contributing to the growth of the market over the coming five years.

The growth of the market is attributed to rising applications of cellular health screening in personalized medicine and increasing government focus on preventive healthcare. The potential applications of cellular health screening in personalized medicine have provided significant growth opportunities to market players in this field. Along with the rapidly growing geriatric population, the demand for cellular screening is expected to rise during the forecast period. According to the World Health Organization Report in October 2021, by 2030, one of every six people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and up is expected to triple, reaching 426 million. The growing geriatric population is more prone to chronic diseases, and thus, this increases the demand for preventive diagnostics, particularly cellular health screening.

Furthermore, the rising chronic illness burden and increasing awareness regarding cellular biomarkers are expected to contribute to the growth of the market. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to increase to 27.5 million new cancer cases worldwide. Such an increase in chronic diseases, such as cancer, is expected to drive the demand for cellular health screening owing to the demand for effective and early diagnosis, thereby contributing to the growth of the market over the forecast period.

Thus, the above-mentioned factors are expected to drive the growth of the market over the forecast period. However, the risks associated with the transport of samples are expected to restrain the growth during the forecast period.

Cellular Health Screening Market Trends

Telomere Tests Segment is Expected to Hold Significant Market Share Over the Forecast Period

The telomere test segment is expected to dominate the market. It accounts for a larger share of the cellular health screening market as these panels are used to get more accurate information and help perform cellular health screening tests to measure the length of the telomere, thereby preventing diseases. Furthermore, with the rising geriatric population, the preference for telomere tests is expected to rise as it facilitates individuals to check their cellular age and thereby take preventive measures, contributing to the growth of the market.

According to the Frontiers research study published in January 2021, telomere had been the most widely used molecular biomarker of aging. Innovative approaches, such as single-cell telomere measurement techniques aimed at the identification of critically short telomeres and DNA methylation-based methods of telomere length estimation, were being developed to improve sensitivity, repeatability, and throughputs of methods used for determining telomere lengths. Such uses of telomere-based tests and developments of improved sensitivity telomere tests are expected to contribute to the growth of the segment over the forecast period.

The rise in the market player's activities, such as product launches, in order to meet the growing demand for telomere tests is expected to contribute to the growth of the segment. For instance, in August 2021, TruDiagnostics released a new report expansion for TruAge, its epigenetic testing service. This expansion gives an accurate estimation of telomere length based on methylation. Thus, the above-mentioned factors are expected to contribute to the growth of the segment over the forecast period.

North America is Expected to Dominate the Cellular Health Screening Market Over the Forecast Period

North America is expected to hold a significant share of the cellular health screening market owing to a high patient pool and rising disease prevalence.

According to Globocon 2020, new cancer cases were diagnosed in 2,281,658 in United States in 2020. Among all cancers, breast cancer had the highest incidence rate, with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809). Also, the data published by the American Cancer Society in 2022 estimated that a total of 1.9 million new cancer cases would occur in United States in 2022. Such increasing incidence of chronic diseases among the population is expected to drive the demand for cellular health screening owing to the effective and early diagnosis, thereby contributing to the growth of the market.

In addition, the Centres for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease was the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in United States. Per the CDC data in October 2022, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of cellular health screening for early diagnosis, driving the market's growth.

Cellular Health Screening Market Competitive Analysis

The cellular health screening market is fragmented due to the presence of several companies operating globally as well as regionally. Some of the global players include Bio-Reference Laboratories Inc., Genova Diagnostics, Immundiagnostik AG, Quest Diagnostics, SpectraCell Laboratories Inc., and Telomere Diagnostics Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Applications of Cellular Health Screening in Personalized Medicine
    • 4.2.2 Increasing Government Focus on Preventive Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Risk Associated With the Transport of Samples
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Single-test Panels
      • 5.1.1.1 Telomere Tests
      • 5.1.1.2 Oxidative Stress Tests
      • 5.1.1.3 Inflammation Tests
      • 5.1.1.4 Heavy Metals Tests
    • 5.1.2 Multi-test Panels
  • 5.2 By Sample Type
    • 5.2.1 Blood Samples
    • 5.2.2 Urine Samples
    • 5.2.3 Other Sample Types
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bio-Reference Laboratories, Inc. (OPKO Health)
    • 6.1.2 Genova Diagnostics
    • 6.1.3 Immundiagnostik AG
    • 6.1.4 Laboratory Corporation of America Holdings
    • 6.1.5 Quest Diagnostics
    • 6.1.6 Segterra Inc.
    • 6.1.7 SpectraCell Laboratories Inc.
    • 6.1.8 Telomere Diagnostics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS